Compare Macy's Inc (M) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Macy's Inc vs Sanofi SA — how do they compare? Macy's Inc trades at $23.35 (market cap $6.13B), while Sanofi SA trades at $44.09 (market cap $104.83B). The key difference: Sanofi SA is far larger — about 17.1× Macy's Inc's market cap, and Sanofi SA pays the higher dividend (5.5%). Which is the better fit depends on your goals.
| M | SNY | |
|---|---|---|
Market Cap | $6.13B | $104.83B |
Sector | Consumer Cyclical | Health |
52-Week High | $25.96 | $52.34 |
52-Week Low | $11.90 | $41.33 |
Enterprise Value | $9.95B | $121.32B |
Dividend Yield | 3.29% | 5.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Macy's (M) trades at $23.39, down 1.22% on the day, with a bullish technical signal supported by moving averages. The stock shows attractive valuation metrics including a P/E of 9.79 and P/S of 0.29, while recent earnings have consistently beaten expectations. Positive sentiment is driven by the 'Bold New Chapter' turnaround strategy, with Berkshire Hathaway's new 3.04 million-share position adding institutional confidence.
The outlook remains cautiously optimistic with a consensus price target of $24.83 offering 6% upside potential. Key opportunities include luxury brand expansion and digital transformation, while risks involve margin pressure from store closures and macroeconomic sensitivity. The stock presents value characteristics with growth catalysts from operational improvements.
SNY trades at $43.97, down 1.55% today, with a bullish technical signal supported by moving averages. The company reported strong Q1 2026 earnings of $1.10 per share, beating expectations, and maintains robust profitability with a 71.92% gross margin. Recent FDA approval for Sarclisa's subcutaneous formulation and expanded AI research collaboration with Aqemia highlight ongoing innovation. Cash flow from operations remains healthy at $10.75 billion for 2025, though net cash flow is minimal at $49 million.
SNY presents a balanced investment case with solid fundamentals and analyst support (44% buy ratings), but faces risks from EU antitrust probes and patent expiration concerns for key drug Dupixent. Valuation metrics appear reasonable with P/E of 19.81 and P/B of 1.29. The stock's outlook depends on successful drug pipeline execution and navigating regulatory challenges, with current price levels offering stability near support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Macy's Inc
Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.
Read more on M →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
